OncoSec Announces Publication of New Research in the Journal Immunity Highlighting the Role of IL-12 in Anti-PD-1 Therapies with TAVO™ Directly Activating TILs in Patients Dec 18, 2018 8:30am EST
OncoSec Reports Updated Tumor Responses in KEYNOTE-695 Study of TAVO™ + KEYTRUDA® in Refractory Metastatic Melanoma Dec 12, 2018 8:00am EST
OncoSec Presents New Data Showing A Single Cycle Of Monotherapy TAVO™ Can Generate Productive Immune Responses In Triple Negative Breast Cancers (TNBC) Dec 11, 2018 8:30am EST
OncoSec Receives $7 Million Investment From Alpha Holdings At $1.50 Per Share Dec 10, 2018 8:30am EST
OncoSec Presents New Data During Oral Presentation At Melanoma Bridge Demonstrating Intratumoral Monotherapy TAVO™ Induces Abscopal Responses In Metastatic Melanoma Patients Nov 29, 2018 8:00am EST
OncoSec To Present Data in Late-Stage Triple Negative Breast Cancer (TNBC) at the 2018 San Antonio Breast Cancer Symposium® Nov 13, 2018 8:00am EST
OncoSec Reports Preliminary Data from KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial of TAVO™ in Combination with KEYTRUDA® for Metastatic Melanoma at Society for Immunotherapy of Cancer's 33rd Annual Meeting Nov 06, 2018 8:00am EST
